Results 91 to 100 of about 4,961 (248)

Restarting Dabigatran Etexilate 24 h After Reversal With Idarucizumab and Redosing Idarucizumab in Healthy Volunteers

Journal of the American College of Cardiology, 2016
Idarucizumab is a specific reversal agent that rapidly neutralizes dabigatran’s anticoagulant activity [(1–3)][1]. We investigated restoration of dabigatran anticoagulation 24 h after idarucizumab treatment and the safety and effectiveness of a second idarucizumab treatment.
Benjamin Lang, Wouter Haazen, Viktoria Moschetti, Jörg Kreuzer, Dietmar Gansser, Stephan Glund, Joachim Stangier, Paul A. Reilly, Stephen Norris, Michael Schmohl, Marina De Smet, Joanne van Ryn   +11 more
openaire   +3 more sources

2017 EACTS Guidelines on perioperative medication in adult cardiac surgery [PDF]

, 2017
To access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked FilesAstraZeneca Boheringer Ingelheim Abbvie Octapharma Orion ...
Castella, Manuel, Collet, Jean-Philippe, Dunning, Joel, Gudbjartsson, Tómas, Head, Stuart J, Jeppsson, Anders, Landmesser*, Ulf, Landoni, Giovanni, Linker, Nick J, Milojevic, Milan, Sandoval, Elena, Sousa-Uva*, Miguel, Thielmann, Matthias   +12 more
core   +1 more source

2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation

Journal of Arrhythmia, Volume 40, Issue 6, Page 1217-1354, December 2024.
Abstract In the last three decades, ablation of atrial fibrillation (AF) has become an evidence‐based safe and efficacious treatment for managing the most common cardiac arrhythmia. In 2007, the first joint expert consensus document was issued, guiding healthcare professionals involved in catheter or surgical AF ablation. Mounting research evidence and
Stylianos Tzeis, Edward P. Gerstenfeld, Jonathan Kalman, Eduardo B. Saad, Alireza Sepehri Shamloo, Jason G. Andrade, Chirag R. Barbhaiya, Tina Baykaner, Serge Boveda, Hugh Calkins, Ngai‐Yin Chan, Minglong Chen, Shih‐Ann Chen, Nikolaos Dagres, Ralph J. Damiano, Tom De Potter, Isabel Deisenhofer, Nicolas Derval, Luigi Di Biase, Mattias Duytschaever, Katia Dyrda, Gerhard Hindricks, Meleze Hocini, Young‐Hoon Kim, Mark la Meir, Jose Luis Merino, Gregory F. Michaud, Andrea Natale, Isabelle Nault, Santiago Nava, Takashi Nitta, Mark O’Neill, Hui‐Nam Pak, Jonathan P. Piccini, Helmut Pürerfellner, Tobias Reichlin, Luis Carlos Saenz, Prashanthan Sanders, Richard Schilling, Boris Schmidt, Gregory E. Supple, Kevin L. Thomas, Claudio Tondo, Atul Verma, Elaine Y. Wan   +44 more
wiley   +1 more source

Management of acute intracerebral haemorrhage – an update [PDF]

, 2017
Managing acute intracerebral haemorrhage is a challenging task for physicians. Evidence shows that outcome can be improved with admission to an acute stroke unit and active care, including urgent reversal of anticoagulant effects and, potentially ...
Al-Shahi Salman, Baharoglu, Connolly, Gomez-Outes, Kirollos, Parry-Jones, Sahni, Steiner, Takeuchi   +8 more
core   +2 more sources

Non-Vitamin K Oral Anticoagulants Associated Bleeding and Its Antidotes [PDF]

Journal of Stroke, 2018
Oral anticoagulant-associated intracerebral hemorrhage (OAC-ICH) accounts for nearly 20% of all ICH. The number of patients with an indication for oral anticoagulant therapy (OAT) increases with increasing age.
Thorsten Steiner, Martin Köhrmann, Peter D. Schellinger, Georgios Tsivgoulis   +3 more
doaj   +1 more source

CDR L3 Loop Rearrangement Switches Multispecific SPE‐7 IgE Antibody From Hapten to Protein Binding

Journal of Molecular Recognition, Volume 37, Issue 6, November 2024.
ABSTRACT The monoclonal IgE antibody SPE‐7 was originally raised against a 2,4‐dinitrophenyl (DNP) target. Through its ability to adopt multiple conformations, the antibody is capable of binding to a diverse range of small haptens and large proteins.
Clarissa A. Seidler, Klaus R. Liedl
wiley   +1 more source

Volume replacement strategies do not impair the binding of dabigatran to idarucizumab: Porcine model of hemodilution.

PLoS ONE, 2019
BackgroundIdarucizumab is a humanized Fab fragment that specifically reverses dabigatran anticoagulation. In trauma, volume expanders are used for resuscitation to compensate for blood loss and hemorrhagic shock, but it is unknown whether volume ...
Oliver Grottke, Joanne van Ryn, Christian Zentai, Guanfa Gan, Markus Honickel, Rolf Rossaint, Hugo Ten Cate, Henri M H Spronk   +7 more
doaj   +1 more source

Management of major bleeding in patients treated with direct oral anticoagulants: from experience to standardized protocols

Italian Journal of Medicine, 2020
Evaluation of clinical-laboratory-therapeutic management and related clinical outcomes (thrombotic-hemorrhagic complications) of patients undergoing treatment with direct oral anticoagulants (DOACs) during major bleeding. This is a two-year observational
Sara Mascia, Anna Maria Ferrari, Nicola Macarone Palmieri, Elisa Romagnoli, Chiara Catena, Serena Scarabottini, Francesca Mori, Lucio Brugioni   +7 more
doaj   +1 more source

Dabigatrán fronte acenocumarol ou warfarina en pacientes con fibrilación auricular [PDF]

, 2018
[Resumo] Introdución: A fibrilación auricular non valvular (FANV) é a arritmia máis frecuente e o ictus a súa principal complicación. Nos pacientes con alto risco de embolización, a terapia anticoagulante demostrou ser altamente eficaz. Os antagonistas
García Costa, Noelia
core  

Best practice in the management of benign prostatic hyperplasia in the patients requiring anticoagulation [PDF]

, 2018
In today's aging population, urologists are often treating older patients with multiple comorbidities. Lower urinary tract symptoms from benign prostate hyperplasia (LUTS/BPH) is a common condition that affects men, with increasing prevalence as men age.
Heiman, Joshua, Krambeck, Amy, Large, Tim   +2 more
core   +1 more source